RNA

A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto
A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto
Endpoints
RNA
Haya Therapeutics
Flag link:
Biogen taps Envisagenics’ AI to speed up RNA splicing R&D
Biogen taps Envisagenics’ AI to speed up RNA splicing R&D
Pharmaforum
Biogen
RNA
drug discovery
Envisagenics
artificial intelligence
Flag link:
Lilly enlists a long-incubating RNA upstart in new $1.25B partnership
Lilly enlists a long-incubating RNA upstart in new $1.25B partnership
Endpoints
MiNA Therapeutic
RNA
Eli Lilly
Flag link:
Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories
Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories
Fierce Biotech
Flagship Pioneering
RNA
Laronde
drug development
Flag link:
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
BioSpace
funding
biotech
IconOVir Bio
oncolytic viruses
cancer
oncology
Aro Biotherapeutics
RNA
Flag link:
Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies
Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies
BioSpace
Locanbio
RNA
gene therapies
funding
Flag link:
Putting a New Spin on RNA, Remix Launches with $81 Million
Putting a New Spin on RNA, Remix Launches with $81 Million
BioSpace
Remix Therapeutics
RNA
Flag link:
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
BioPharma Dive
AstraZeneca
Accent Therapeutics
cancer
RNA
Flag link:
AstraZeneca-partnered RNA player Silence plans Nasdaq listing
AstraZeneca-partnered RNA player Silence plans Nasdaq listing
Fierce Biotech
Silence Therapeutics
RNA therapeutics
RNA
NASDAQ
AstraZeneca
gene silencing
Flag link:
Merck doubles down on Skyhawk's tech to drug RNA, promising $600M per autoimmune, metabolic target
Merck doubles down on Skyhawk's tech to drug RNA, promising $600M per autoimmune, metabolic target
Endpoints
Merck
Skyhawk Therapeutics
small molecule drugs
RNA
R&D
Flag link:
It's not developing drugs that bind to RNA, or morphing RNA into a therapeutic — this Cambridge startup has scored $63M to work on RNA-modifying proteins
It's not developing drugs that bind to RNA, or morphing RNA into a therapeutic — this Cambridge startup has scored $63M to work on RNA-modifying proteins
Endpoints
Accent Therapeutics
RNA
Flag link:
AstraZeneca gets in on RNA game with MiNA research collaboration
AstraZeneca gets in on RNA game with MiNA research collaboration
Endpoints
AstraZeneca
RNA
MiNA
R&D
Flag link:
Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies
Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies
CP Wire
Exosome Diagnostics
diagnostics
Bio-Techne
prostate cancer
lung cancer
RNA
Flag link:
Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies
Exosome Diagnostics
diagnostics
Bio-Techne
prostate cancer
lung cancer
RNA
Flag link:
A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins
A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins
Stat
Arrakis Therapeutics
RNA
cancer
Flag link:
Ambry Genetics Makes Advances in RNA Genetic Testing
Ambry Genetics Makes Advances in RNA Genetic Testing
BioSpace
Ambry Genetics
diagnostics
RNA
genetic testing
Flag link:
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
CP Wire
biotech
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Flag link:
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Flag link:
Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA
Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA
Endpoints
Merck
Amgen
Ribometrix
RNA
Flag link:
GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up
GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up
Xconomy
GSK
Ionis
familial amyloid polyneuropathy
RNA
inotersen
Flag link:

Pages